Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Early Onset Cataracts > Oral sedation shows strong safety profile for office-based cataract surgery
  • Early Onset Cataracts

Oral sedation shows strong safety profile for office-based cataract surgery

Ophthalmology 360

Key Takeaways

  1. Oral diazepam showed no sedation-related adverse events and an extremely low complication rate (0.14%).
  2. Average 82-minute arrival-to-discharge supports office-based cataract surgery.
  3. Oral sedation provides a reliable, effective alternative to IV sedation, with optional MKO Melt support.

Oral sedation with diazepam is a safe, effective, and efficient alternative to IV sedation for cataract surgery in an office-based setting, with no sedation-related complications and very low intraoperative risk, according to a presentation at AAO 2025.

The analysis evaluated patient sedation protocols, adverse events, procedure efficiency, and intraoperative complications in 729 consecutive cataract surgeries. Patients received either 5 mg of diazepam (28%), 10 mg of diazepam (62%), or 10 mg of diazepam combined with MKO Melt (10%) prior to surgery. The average time from arrival to discharge was 82 minutes, demonstrating procedural efficiency suitable for an outpatient environment.

No adverse events related to sedation were reported, and no surgeries were canceled after sedation was initiated. Only one intraoperative complication occurred (a vitreous prolapse), resulting in a complication rate of 0.14%.

The authors concluded that oral sedation with diazepam, with optional MKO Melt supplementation, offers a safe and reliable alternative to intravenous sedation for cataract surgery in an office-based setting suite.

Reference
Redding CL, et al. Office-Based Cataract Surgery With Oral Sedation. Poster presented at: American Academy of Ophthalmology Annual Meeting; October 18–20, 2025; Orlando, FL.

Share

Related Content

  • Glaucoma

Review finds low adverse event rates for glaucoma stents

  • Retina

Switching to aflibercept 8 mg extends treatment intervals in suboptimal nARMD responders

  • Conference Roundup

Cryopreserved amniotic membrane significantly improves ocular surface integrity in patients with severe keratoconjunctivitis sicca and neurotrophic keratopathy

  • Conference Roundup

CAM360 with a collagen shield provides rapid epithelial healing with better tolerability and safety than when used with bandage contact lenses

  • Conference Roundup

Enhanced monofocal IOLs provide better intermediate vision with no rings or dysphotopsia

  • Conference Roundup

Phase 1/2 CLARA study shows AURN001 improves BCVA compared with standard of care for corneal endothelial dysfunction

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon